Biodistribution and pharmacokinetics of recombinant, human 125I-interleukin-2 in mice

This publication has 16 references indexed in Scilit:

• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2
  Cancer Immunology, Immunotherapy, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
  The Journal of Immunology, 1985
• Retention of biological activity following radioiodination of human interleukin 2: Comparison with biosynthetically labeled growth factor in receptor binding assays
  Journal of Immunological Methods, 1985
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
  The Journal of Experimental Medicine, 1985
• Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen.
  The Journal of Experimental Medicine, 1984
• Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
  Science, 1984
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
  Biochemical Journal, 1963